Emergent BioSolutions Receives $22.3 Million Delivery Order Modification to Supply BioThrax® (Anthrax Vaccine Adsorbed) to the U.S. Department of War
Emergent BioSolutions Inc. (EBS) filed an SEC Form 8-K — Other Events. Emergent BioSolutions Receives $22.3 Million Delivery Order Modification to Supply BioThrax ® (Anthrax Vaccine Adsorbed) to the U.S. Department of War GAITHERSBURG, Md., Nov. 04, 2026 (BUSINESSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that it has received a
- Role
- supplier
- Counterparty
- U.S. Department of War
- Value
- $22.3 million
- Duration
- remaining deliveries are expected in 2027
Facts are quoted from the filing text and checked against it. Details that could not be matched to the text are left out.
How this was made
The 30-second read
Why it matters
The $22.3 million order modification provides a near‑term revenue boost and underscores the company's strategic role in national security.
Market read
The announcement may lift EBS modestly while highlighting continued government demand for biodefense products.
What to watch
Potential supply chain constraints or future budget cuts could limit subsequent deliveries.
Background
Emergent BioSolutions is a leading provider of biodefense vaccines, with BioThrax being the only FDA‑approved anthrax vaccine in the U.S.
Ticker impact
Emergent BioSolutions disclosed a $22.3 million contract modification to supply BioThrax to the U.S. Department of War, with the first $7.4 million delivery this year.
likely modest upside as investors price in the additional revenue stream
The contract is a fresh, material government award that directly boosts near‑term earnings expectations.
Market effects
Strengthens outlook for defense and biodefense stocks as government spending on bio‑threat countermeasures rises.
Limited to U.S. defense contractors; minimal broader market effect.
Reinforces confidence in U.S. government contracts for biotech firms globally.
Counterpoint
The contract size is modest relative to the company's market cap; investors may already price it in.
Key entities
- companyEmergent BioSolutions Inc.
U.S. biotech firm supplying BioThrax anthrax vaccine to the Department of War.
- governmentU.S. Department of War
Federal customer receiving the vaccine under an IDIQ contract.



